Showing 1,095 results

Filters Content type: News, Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment

Gilead Limits Enrollment in its Hep C Patient Program to Pressure Insurers

Editor's pick
Wall Street Journal Pharmalot blog
20 July 2015
Hepatitis & HIV

Access to screening and treatment are key issues for hepatitis B and C and HIV/viral hepatitis co-infection

News
20 July 2015
Hepatitis C treatment

Gilead Limits Enrollment in its Hep C Patient Program to Pressure Insurers

Editor's pick
Wall Street Journal
19 July 2015
People who inject drugs

Improving access to, and completion of, hepatitis C treatment

Editor's pick
Public Health England
17 July 2015
New & experimental hepatitis C treatment

Gilead pills priced at $1,000 a day are found cost-effective

Editor's pick
Bloomberg
14 July 2015
Hepatitis C treatment

National study finds life-threatening barriers in access to breakthrough drugs

Editor's pick
Eurekalert
30 June 2015
New & experimental hepatitis C treatment

FDA is Sued by Advocacy Groups That Want Gilead Hepatitis C Trial Data

Editor's pick
Wall Street Journal (blog)
29 June 2015
Hepatitis C treatment

Adding ribavirin to Harvoni for hepatitis C increases side effects but not efficacy

Editor's pick
HIVandHepatitis.com
29 June 2015
Hepatitis C treatment

Liver transplants in HIV/HCV co-infection: study underlines importance of hepatitis C treatment

News
26 June 2015
Hepatitis C symptoms & diagnosis

Hepatitis C Virus Infection and Alcohol: Challenges and Opportunities

Editor's pick
HCV Action
24 June 2015
Hepatitis C treatment

AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis

Editor's pick
AbbVie press release
24 June 2015
Hepatitis C treatment

Burman's Specialty Pharmacy study shows hepatitis C cure possible while cutting a third of the drug costs

Editor's pick
Burman's Specialty Pharmacy press release
24 June 2015
Access to healthcare

China rejects Gilead hepatitis C drug patent: advocacy group

Editor's pick
Reuters
19 June 2015
Hepatitis C treatment

Liver function and survival improve after treatment with Viekirax + Exviera regimen

News
18 June 2015
Hepatitis C treatment

Hepatitis C: 25 Years Old, and Fading

Editor's pick
Medscape
17 June 2015
Hepatitis C treatment

NHS accused of delaying access to 'highly tolerable' hepatitis C drugs over cost concerns

Editor's pick
The Independent
17 June 2015
Hepatitis C treatment

Prisoners Sue Massachusetts for Withholding Hepatitis C Drugs

Editor's pick
Wall Street Journal (blog)
16 June 2015
Hepatitis C treatment

NHS England announces 'huge investment' for new hepatitis C treatments

Editor's pick
The Pharmaceutical Journal
16 June 2015
Hepatitis C treatment

HCV at a Crossroads:The Pre- or Post-Transplant Treatment Debate

Editor's pick
Healio HCV Next
15 June 2015
Hepatitis C treatment

NHS England stumps up £190m for hep C therapy

Editor's pick
Pharma Times
12 June 2015
Hepatitis C treatment

Pharma Execs Don't Know Why Anyone Is Upset by a $94,500 Miracle Cure

Editor's pick
Bloomberg
9 June 2015
Hepatitis C treatment

Treatment For Welsh Hepatitis C Patients With Advanced Liver Disease

Editor's pick
Swansea Sound
8 June 2015
Hepatitis C transmission & prevention

Hepatitis C treatment could halve HCV transmission among gay men in UK over 10 years

News
5 June 2015
Hepatitis C transmission & prevention

Reinfection after hepatitis C cure: prevention may require long-term support for people who have injected drugs

News
4 June 2015